Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare a Dry Powder Oral Suspension (10 mg and 20 mg Dose of Rivaroxaban) With an Oral Suspension (10 mg of Rivaroxaban) and 10 mg of an Immediate Release Tablet Under Fasting Conditions (10 mg Doses) and Under Fed Conditions (20 mg Dose) in Healthy Male Subjects

Trial Profile

Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare a Dry Powder Oral Suspension (10 mg and 20 mg Dose of Rivaroxaban) With an Oral Suspension (10 mg of Rivaroxaban) and 10 mg of an Immediate Release Tablet Under Fasting Conditions (10 mg Doses) and Under Fed Conditions (20 mg Dose) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Rivaroxaban (Primary) ; Rivaroxaban (Primary)
  • Indications Thromboembolism; Thrombosis
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 09 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 09 Mar 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 24 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top